Rubraca
(Rucaparib)Phase 3Small molecule
Bristol-Myers SquibbRucaparib is used to treat certain types of ovarian cancer and breast cancer, particularly in patients whose tumors have specific genetic mutations that make them sensitive to this drug.[1] Rubraca is currently being investigated across 18 indications[3], with its most advanced program in Phase 3.[1]
Rubraca is one of 442 small molecule programs targeting Peritoneum Cancer. It is currently in Phase 3.
18
Indications
60
Total Trials
9
Active Trials
441
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Rubraca
Bristol-Myers SquibbPhase 3
Trodelvy
GileadPreclinical
Tecentriq
RochePreclinical
Avastin
BBio-Thera Solutions
Preclinical
Voltaren
NovartisPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer9 trials
Show 6 more trials
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Active, not recruiting·—·Phase 1/2·NCT04253262·13 enrolled
Ovarian Cancer6 trials
Show 3 more trials
Bevacizumab3 trials
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Active, not recruiting·—·Phase 2·NCT02873962·73 enrolled
Primary Peritoneal Cancer3 trials
28 more indications
Endometrial Cancer2 trials
Gastric Cancer2 trials
Pancreatic Cancer2 trials
Interaction2 trials
Solid Tumors2 trials
Non-Small Cell Lung Cancer2 trials
Solid Tumor2 trials
Urothelial Carcinoma1 trial
Fallopian Tube Cancer1 trial
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT03462212·290 enrolled
Esophageal Adenocarcinoma1 trial
Small Cell Cancer1 trial
Biliary Tract Cancer1 trial
Triple-Negative Breast Cancer1 trial
Efficacy and Safety1 trial
Pain1 trial
Advanced Malignancies1 trial
Malignant Mesothelioma1 trial
Absorption1 trial
Triple Negative1 trial
Biliary Cancer1 trial
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Active, not recruiting·—·Phase 1/2·NCT03337087·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rucaparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- PARP 1, 2 and 3 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company